Skip to main content
NewslettersWatchlist

Takeda Pharmaceutical Ltd ADR(TAK-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low13.52
Day High13.75
Open:13.53
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
PR Newswire
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD
MarketBeat
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
PressReach
New Study Reveals How Classical Music Could Revolutionize Depression Care
Barchart
3 'Strong Buy'-Rated Stocks to Buy Now on the Dip
Motley Fool
One Ultra-Cheap High-Yield Dividend Stock to Buy
AllPennyStocks.com
Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time
PR Newswire
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
Motley Fool
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
Motley Fool
2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now
Motley Fool
Why Shares of Innate Pharma Jumped Thursday
The Globe and Mail
7 Japanese companies with sustainable dividends
Business Wire
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
Motley Fool
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
Motley Fool
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Business Wire
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
Business Wire
Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners
Business Wire
Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
Business Wire
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
Business Wire
BioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.
MarketBeat
Price Growth & Yield: For That Magical Combo, Leave the U.S.
Business Wire
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
Motley Fool
Should You Give Up on Novavax?

Profile

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.